Late-breaking data show reliable performance of small-diameter defibrillation lead, the medtronic omniasecure™

Global leadr clinical trial meets safety and effectiveness objectives; results presented at heart rhythm 2024 and simultaneously published in heart rhythm dublin and boston , may 17, 2024 /prnewswire/ -- medtronic plc (nyse: mdt), a global leader in healthcare technology, announced that its investigational omniasecure™ defibrillation lead met its primary safety and effectiveness endpoints, exceeding prespecified performance goals, in the global lead evaluation for defibrillation and reliability (leadr) pivotal trial. late breaking results were presented at heart rhythm 2024 and simultaneously published in the journal heart rhythm.
MDT Ratings Summary
MDT Quant Ranking